Study Title: Modeling first-line daratumumab use for newly diagnosed, transplant-ineligible, multiple myeloma: a cost-effectiveness and risk analysis for health care payers

Authors: Bayani DB, Lin YHC, Nagarajan C, Ooi MG, Yso ACY, Cairns J, Wee HL

Corresponding Author: DB Bayani | dbayani@u.nus.edu

Instructions per section below:

Partitioned Survival Analysis: Patient-level data or pseudo patient-level data must be available for each trial. To generate pseudo patient-level data, a digitizer software must be used together with the validated algorithm by Guyot, et al. This can also be constructed via this link: https://www.trialdesign.org/one-page-shell.html#IPDfromKM

Risk Analysis: The code for running a probabilistic sensitivity analysis on R using the partitioned survival model is presented below. For each scenario or scheme implemented, a different .csv file must be saved for parameter values, costs, and outcomes. The outputs may be uploaded onto https://savi.shef.ac.uk/SAVI/ to generate the EVPI/P-SUB outputs.

History: 4/21/2024: Codes uploaded